LACTOLOGY FOUNDATION

A10AB03 — Porcine Insulin (Insulin Pork): Academic Toxicological and Lactological Monograph

1. ATC Classification and Pharmacological Profile

A10AB03 designates insulin (pork), or porcine insulin, within the Anatomical Therapeutic Chemical classification hierarchy A10 (Drugs used in diabetes), A10A (Insulins and analogues), and A10AB (Insulins and analogues for injection, fast-acting). Historically, porcine insulin was one of the principal animal-derived insulin preparations used for the treatment of diabetes before recombinant human insulin and modern insulin analogues became widely available.

Porcine insulin is a peptide hormone traditionally isolated and purified from porcine pancreatic tissue. Structurally, it is exceptionally similar to human insulin. The two molecules differ by only one amino-acid residue at position B30: porcine insulin contains alanine, whereas human insulin contains threonine. This close structural homology explains their broadly comparable receptor-mediated biological activity. PubMed Central (PMC)

Like human insulin, porcine insulin consists of A and B polypeptide chains connected by disulfide bonds. Its pharmacological effects result from binding to the insulin receptor, a transmembrane receptor tyrosine kinase. Activation of the receptor initiates intracellular signaling pathways that increase peripheral glucose uptake, particularly in skeletal muscle and adipose tissue, while reducing hepatic glucose output. Insulin also suppresses lipolysis and proteolysis and promotes glycogen, lipid, and protein synthesis.

Within A10AB03, porcine insulin is classified as a fast-acting injectable insulin preparation. Its therapeutic function is therefore primarily related to controlling meal-associated glucose excursions and providing short-duration insulin replacement. The exact pharmacokinetic and pharmacodynamic profile varies with formulation, dose, route and site of administration, local tissue perfusion, physical activity, and individual metabolic characteristics.

Porcine insulin has greater structural similarity to human insulin than bovine insulin, which differs from human insulin at three amino-acid positions. Consequently, purified porcine insulin has historically exhibited lower immunogenic potential than bovine preparations, although porcine insulin remains capable of inducing insulin antibodies and allergic reactions. Wiley Online Library

Animal-source insulin has largely been displaced by recombinant human insulin and insulin analogues in contemporary clinical practice. This decline in use has important implications for lactological assessment because modern substance-specific data for porcine insulin are considerably less extensive than those available for contemporary recombinant preparations.

2. Toxicological Profile

The toxicological profile of porcine insulin is dominated by excessive pharmacological insulin activity, with hypoglycemia constituting the principal acute hazard. This toxicity is fundamentally dose-related and is pharmacodynamically comparable to hypoglycemia caused by other insulin preparations.

Hypoglycemia may result from excessive insulin dosing, insufficient carbohydrate intake, delayed or omitted meals, increased physical activity, changes in insulin sensitivity, renal or hepatic dysfunction, acute illness, medication interactions, or administration errors. The rapid-action characteristics associated with A10AB preparations make appropriate coordination between insulin administration and carbohydrate availability particularly important.

Clinical manifestations include autonomic symptoms such as sweating, tremor, hunger, anxiety, and palpitations and neuroglycopenic manifestations including weakness, impaired concentration, behavioral abnormalities, confusion, visual disturbances, seizures, loss of consciousness, and coma. Severe or prolonged hypoglycemia may cause permanent neurological injury and can be fatal.

Substantial insulin excess can additionally produce hypokalemia because insulin promotes cellular uptake of potassium. Severe hypokalemia may contribute to muscle weakness, electrophysiological abnormalities, and potentially serious cardiac arrhythmias.

Repeated subcutaneous administration may result in injection-site reactions and local lipodystrophic changes. Weight gain and edema are additional effects associated with insulin treatment in general.

A toxicologically relevant characteristic of porcine insulin is its immunogenic potential. Because it differs structurally from endogenous human insulin, porcine insulin can induce antibody formation. Historical and experimental evidence confirms antigenicity in humans, although its immunogenicity is generally lower than that of bovine insulin and is also influenced substantially by the purity of the insulin preparation. PubMed

Older animal insulin preparations sometimes contained pancreatic impurities, including proinsulin and other peptides, which contributed to their immunogenicity. Improved purification substantially reduced this problem. Thus, adverse-effect data obtained with early animal-derived preparations cannot necessarily be extrapolated quantitatively to highly purified porcine insulin. PubMed Central (PMC)

During lactation, the major practical toxicological concern is maternal hypoglycemia rather than toxicity in the nursing infant. Postpartum insulin requirements frequently decrease substantially compared with pregnancy requirements. Insulin doses must therefore be reassessed following delivery and subsequently individualized as maternal metabolism, nutrition, physical activity, and lactation patterns evolve. Current LactMed guidance confirms reduced postpartum insulin requirements in women with type 1 diabetes, although the magnitude of the reduction varies considerably between individuals. NCBI

3. Lactation Pharmacology and Breast-Milk Exposure

Porcine insulin is particularly interesting from a lactation-pharmacology perspective because direct experimental evidence demonstrates its appearance in human breast milk.

Insulin itself is a normal physiological constituent of human milk. Contemporary LactMed data report measurable endogenous insulin concentrations in breast milk and confirm that exogenous insulin can also be excreted into milk. NCBI

Importantly, an experimental study specifically evaluated regular porcine insulin in lactating women. Seven women with diabetes and ten women without diabetes underwent intravenous glucose administration, after which regular pork insulin was administered intravenously to reduce blood glucose. In the women with diabetes, milk insulin concentrations increased, with peak concentrations occurring approximately 30–50 minutes after intravenous porcine insulin administration. This provides direct evidence that maternally administered porcine insulin can reach human milk. NCBI

However, detection in milk must not be equated with clinically significant systemic exposure of the breastfed infant.

Porcine insulin is a polypeptide and, like endogenous human insulin, is susceptible to enzymatic degradation within the gastrointestinal tract. Orally ingested insulin consequently has extremely poor systemic bioavailability. Most insulin reaching the infant through milk would be expected to undergo gastrointestinal proteolysis rather than enter the systemic circulation as pharmacologically active intact insulin.

This pharmacokinetic property substantially limits the usefulness of a conventional relative infant dose (RID) assessment. For an orally bioavailable small molecule, the milk dose can provide a useful approximation of potential infant exposure. For porcine insulin, however, the quantity swallowed substantially overestimates pharmacologically active systemic exposure because gastrointestinal absorption of intact insulin is negligible.

The direct demonstration of porcine insulin in breast milk therefore represents evidence of milk transfer, not evidence of clinically important infant insulin exposure.

LactMed's current assessment of insulin supports this distinction: exogenous insulin is excreted into human milk, yet mothers requiring insulin therapy may breastfeed. Furthermore, enteral recombinant insulin has been administered directly to premature infants without establishing clinically significant systemic insulin toxicity. NCBI

Porcine insulin differs from human insulin by only a single amino acid, but this structural difference warrants some caution when extrapolating evidence regarding local gastrointestinal or immunological effects. Nevertheless, there is no established evidence that the small quantities potentially ingested through breast milk produce clinically important systemic or immune-mediated effects in nursing infants.

4. Effects in the Breastfed Infant and on Lactation

No established pattern of clinically significant adverse effects in breastfed infants has been attributed to therapeutic maternal porcine insulin.

Most importantly, clinically significant infant hypoglycemia resulting from porcine insulin in breast milk is not expected. Although direct experimental evidence confirms that maternal porcine insulin can increase milk insulin concentrations, the peptide nature of the molecule and its negligible oral systemic bioavailability provide a strong pharmacological barrier to systemic glucose-lowering effects in the infant. NCBI

Current LactMed guidance considers maternal insulin therapy compatible with nursing and does not identify milk-mediated infant hypoglycemia as an expected adverse effect. Insulin is physiologically present in human milk, and available evidence concerning oral exposure further supports a favorable safety assessment. NCBI

The structural difference between porcine and human insulin introduces a theoretical question regarding oral immunological exposure. Porcine insulin is demonstrably antigenic following parenteral administration in humans. PubMed However, parenteral immunogenicity cannot be directly extrapolated to the very small quantities ingested orally through breast milk. No convincing clinical evidence establishes sensitization, allergy, insulin-antibody formation, or other clinically important immune-mediated effects in breastfed infants as a consequence of maternal porcine insulin treatment.

The effects of maternal diabetes on lactation are clinically more relevant than direct adverse effects of porcine insulin on the mammary gland. Insulin has physiological roles in mammary metabolism, and adequate insulin activity and glycemic control contribute to normal lactational physiology.

Women with diabetes may experience delayed lactogenesis under some circumstances, but this should not be interpreted as evidence that therapeutic insulin inhibits milk production. Rather, diabetes-associated metabolic disturbance, glycemic control, maternal characteristics, obstetric factors, and perinatal circumstances can influence the initiation and maintenance of lactation.

Current LactMed evidence indicates that insulin is a normal milk component and that appropriate maternal insulin therapy is compatible with breastfeeding. NCBI

Thus, clinically adequate treatment of maternal diabetes should be regarded as supportive of maternal metabolic stability during lactation rather than as a pharmacological impediment to breastfeeding.

5. Lactological Safety Assessment and Clinical Recommendations

A10AB03 porcine insulin is considered compatible with breastfeeding on the basis of direct milk-transfer evidence, insulin pharmacology, historical clinical experience, and contemporary class-level lactation data.

The evidence is particularly informative because porcine insulin, unlike some historical animal-derived insulin preparations, has been directly studied in lactating women. Regular pork insulin administered intravenously was demonstrably transferred into breast milk, but this finding has not translated into evidence of clinically significant toxicity in breastfed infants. NCBI

The principal determinants of its favorable lactological assessment are that insulin is naturally present in breast milk, porcine insulin differs only minimally from human insulin, and ingested insulin undergoes extensive gastrointestinal degradation with negligible systemic oral bioavailability. PubMed Central (PMC)

Maternal therapy therefore does not ordinarily require interruption of breastfeeding, disposal of expressed milk, or deliberate separation of breastfeeding from insulin administration. Although milk concentrations can rise after maternal administration, timing feeds to avoid such concentrations is unlikely to confer meaningful additional protection because systemic infant absorption, rather than milk transfer itself, is the critical limiting factor.

Routine measurement of infant glucose concentrations is not required solely because the mother receives porcine insulin. Clinical evaluation remains appropriate when a breastfed infant develops unexplained symptoms compatible with hypoglycemia or another metabolic disorder, particularly in premature or medically unstable infants, but such manifestations should not automatically be attributed to maternal insulin therapy.

Maternal management requires substantially greater attention. Insulin requirements should be reassessed promptly after delivery and adjusted according to glucose monitoring, carbohydrate intake, feeding pattern, physical activity, renal function, intercurrent illness, and other determinants of insulin sensitivity. Prevention of severe maternal hypoglycemia is particularly important because impaired consciousness or coordination creates an indirect safety risk during infant feeding and care. NCBI

Mothers should have rapid-acting carbohydrate readily accessible and should receive individualized guidance regarding recognition and treatment of hypoglycemia. Where appropriate, continuous glucose monitoring or frequent capillary glucose assessment may facilitate safe postpartum dose adjustment.

The historical immunogenicity of porcine insulin should also be considered independently from lactational exposure. Porcine insulin is more immunogenic than human insulin, although considerably closer structurally to human insulin than bovine insulin. Modern availability of animal-source insulin is limited in some healthcare systems, and therapeutic selection may consequently favor recombinant preparations for reasons unrelated to breastfeeding. Wiley Online Library

If a woman is clinically stable on porcine insulin, however, breastfeeding itself does not constitute a pharmacological reason to discontinue or replace the insulin solely to prevent infant exposure.

6. Conclusion

A10AB03 represents fast-acting porcine (pork) insulin, an animal-derived insulin preparation with a molecular structure exceptionally close to that of human insulin. Porcine and human insulin differ by only one amino acid at the B30 position, allowing porcine insulin to exert essentially the same insulin-receptor-mediated metabolic actions while retaining somewhat greater immunogenic potential than human insulin. PubMed Central (PMC)

Its principal toxicological hazard is excessive pharmacological activity causing maternal hypoglycemia. Severe overdose may additionally cause hypokalemia, while chronic treatment can be associated with injection-site reactions, lipodystrophy, antibody formation, and occasional hypersensitivity.

The lactation evidence for porcine insulin is notable because direct experimental observations demonstrate increased breast-milk insulin concentrations following maternal administration of regular pork insulin. Nevertheless, milk transfer does not imply clinically significant systemic infant exposure. Porcine insulin is a peptide that is extensively degraded within the gastrointestinal tract and has negligible oral systemic bioavailability. NCBI

No established evidence indicates clinically important hypoglycemia or other systemic toxicity in breastfed infants resulting from therapeutic maternal porcine insulin. Contemporary LactMed guidance supports breastfeeding during maternal insulin therapy and recognizes insulin as a normal physiological component of human milk. NCBI

Accordingly, maternal A10AB03 therapy is compatible with breastfeeding, and routine interruption of nursing, disposal of breast milk, dose-to-feed separation, or infant biochemical monitoring is generally unnecessary. The major clinical priority is individualized maternal insulin adjustment during the postpartum period and prevention of maternal hypoglycemia.